Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Nitrogen containing other than solely as a nitrogen in an...
Reexamination Certificate
2007-09-25
2007-09-25
Kwon, Brian (Department: 1614)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Nitrogen containing other than solely as a nitrogen in an...
C514S657000, C514S665000
Reexamination Certificate
active
10256283
ABSTRACT:
The present invention is directed to pharmaceutical compositions of effective amounts of NMDA receptor antagonists and preservative for the administration to a patient in need of effective analgesia and anesthesia. The compositions of the invention advantageously do not cause any significant neurotoxicity. The preferred NMDA receptor antagonist is ketamine. The preferred preservative is benzalkonium chloride.
REFERENCES:
patent: 3760077 (1973-09-01), Thompson et al.
patent: 4017619 (1977-04-01), Burnap
patent: 5352683 (1994-10-01), Mayer
patent: 5384331 (1995-01-01), Kogan et al.
patent: 5543434 (1996-08-01), Weg
patent: 5654281 (1997-08-01), Mayer
patent: 5834465 (1998-11-01), Olney
patent: 5919826 (1999-07-01), Caruso
patent: 6200990 (2001-03-01), Namil et al.
patent: 6248789 (2001-06-01), Weg
patent: 6509028 (2003-01-01), Williams et al.
patent: 6638981 (2003-10-01), Williams et al.
patent: 1330878 (1973-09-01), None
patent: WO9851282 (1998-11-01), None
patent: WO- 00/24396 (2000-05-01), None
“Creative Developments (Cosmetics) Limited: Surfactants 1999”, www.creative-developments.co.uk, 1999.
“Benzalkonium Chloride”, www.en.wilipedia.org., 2006.
R. Schmid et al.: “Use and efficacy of low-dose ketamine in the management of acute postoperative pain: a review of current techniques and outcomes,” Pain, Amsterdam, vol. 82, No. 2, 1999, pp. 111-125.
Ahuja, Br. J. Anaesth. 1983, 55:991.
Battacharya et al., Ann. Acad. Med. Singapore 1994, 23:456.
Bookwalter, Plastic Surg. Nursing 1994, 14:43.
Brock-Utne et al., S.A. Med. J. 1982, 20:440.
Clark and Kalan, J. Pain Symptom. Manage. 1995, 10:310.
Collingridge et al., The NMDA Receptor, Oxford University Press, 1994.
Dich-Nielsen et al., Acta Anaesthesiol. Scand. 1992, 36:583.
Eide et al. Pain 1994, 58:347.
Errando et al. Reg. Anesth and Pain Med.1999, 24:136.
Fine,, J. Pain Symptom Manage. 1999, 17:296.
Fix et al, Experimental Neurology 1993, 123:204-215.
Fix et al., Toxicol. Pathol. 1996, 24:291-304.
Physicians' Desk Reference, 1986 Edition, Product Information, Cover page and pp. 1356-1358.
Mary Ellen Clinton et al., “Effects of Phenytoin, Ketamine, and Atropine Methyl Nitrate in Preventing Neuromuscular Toxicity of Acetylcholinesterase Inhibitors Soman and Diiospropylphosphorofluoridate”, Journal of Toxicology and Environmental Health, 1988, Cover pages and pp. 439-449.
J.W. Olney et al., “NMDA Antagonist Neurotoxicity: Mechanism and Prevention”, Science, vol. 254, Dec. 6, 1991, pp. 1515-1518.
Foster et al., Nature 1987, 329:395-396.
Gebhardt, Anaesthesist 1994, 43 (suppl.2):S34.
Gurnani et al., Anaesth. Intens. Care 1996, 24:32.
Hirlinger and Pfenninger, Anaesthsist 1987, 36:140.
Humphries e al., J. Burn Care Rehabil. 1997, 18:34.
Jevotovic-Todorovic et al., Brain Res 2001, 895;264.
Karpinski et al., Pain 1997, 73:103.
Kuboyama et al., J. Toxicol. Sci. 1997, 22:153.
Lauretti et al., Anesthesiology 1999, 90:1528.
Malinovsky et al., Anesthesiology 1991, 75:91.
Malinovsky et al., Anesthesiology 1993, 78:109.
Mathisen et al., Pain 1995, 61:215.
Mayer et al., Trends in Pharmacol. Sci. 1990, 11:254-260.
Mercadante et al., J. Pain Symptom Manage. 1995, 10:564.
Naguib et al., Can. Anaesth. Soc. J. 1986, 33:16.
Olney et al., Science 1989, 244:1360.
Shahar et al., Neurochem. Res. 1989, 14:1017.
Wlaz et al., Eur. J. Neurosci. 1994; 6:1710-1719.
Knox et al., Anaesth Intens Care 1995, 23:620-622.
Christophe Baudouin et al., Short term comparative study of topical 2% carteolol with and without benzalkonium chloride in healthy volunteers, British Jounal of Ophthalmology, vol. 82, pp. 39-42 (1998).
Neal L. Burstein, Preservative cytotoxic threshold for benzalkonium chloride and chlorhexidine digluconate in cat and rabbit corneas, Investigative Ophthalmology and Visual Science, vol. 19, pp. 308-313 (1980).
Albin Randi
Mermelstein Fred H.
Innovative Drug Delivery Systems, Inc.
Kwon Brian
LandOfFree
NMDA receptor antagonist formulation with reduced neurotoxicity does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with NMDA receptor antagonist formulation with reduced neurotoxicity, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and NMDA receptor antagonist formulation with reduced neurotoxicity will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3745852